JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Haemonetics Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

52.28 -2.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

52.24

Max

54.46

Pagrindiniai rodikliai

By Trading Economics

Pajamos

20M

58M

Pardavimai

-18M

331M

P/E

Sektoriaus vid.

22.574

34.393

Pelnas, tenkantis vienai akcijai

1.24

Pelno marža

17.538

Darbuotojai

3,023

EBITDA

-19M

71M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+40.77% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

488M

3.7B

Ankstesnė atidarymo kaina

54.43

Ankstesnė uždarymo kaina

52.28

Naujienos nuotaikos

By Acuity

59%

41%

319 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Haemonetics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-11 17:49; UTC

Pagrindinės rinkos jėgos

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025-08-11 17:18; UTC

Pagrindinės rinkos jėgos

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025-08-11 16:25; UTC

Uždarbis

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025-08-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-08-11 23:42; UTC

Rinkos pokalbiai

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025-08-11 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025-08-11 23:32; UTC

Rinkos pokalbiai

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025-08-11 23:02; UTC

Rinkos pokalbiai

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025-08-11 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025-08-11 20:37; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025-08-11 20:22; UTC

Uždarbis

Exodus Movement 2Q Rev $25.8M >EXOD

2025-08-11 20:14; UTC

Rinkos pokalbiai

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025-08-11 19:12; UTC

Rinkos pokalbiai

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025-08-11 18:56; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025-08-11 18:31; UTC

Rinkos pokalbiai

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025-08-11 17:43; UTC

Rinkos pokalbiai

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025-08-11 17:28; UTC

Rinkos pokalbiai

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025-08-11 17:16; UTC

Rinkos pokalbiai

Commodity Longs Fall to 11-Month Low -- Market Talk

2025-08-11 16:42; UTC

Įsigijimai, susijungimai, perėmimai

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025-08-11 16:27; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Says Sabadell Offer Remains in Effect

2025-08-11 16:26; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Announced TSB Sale on July 1

2025-08-11 16:25; UTC

Įsigijimai, susijungimai, perėmimai

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Akcijų palyginimas

Kainos pokytis

Haemonetics Corp Prognozė

Kainos tikslas

By TipRanks

40.77% į viršų

12 mėnesių prognozė

Vidutinis 76 USD  40.77%

Aukščiausias 100 USD

Žemiausias 61 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Haemonetics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

8

Pirkti

2

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

62.51 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

319 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.